Abstract
AbstractClinically significant portal hypertension (CSPH), defined as a hepatic venous pressure gradient (HVPG) ≥ 10 mmHg, is an independent risk factor for decompensated events in patients with compensated cirrhosis. Currently, the Baveno VII consensus recommends using nonselective beta‐blockers to treat compensated cirrhosis in patients with CSPH. Here, we report a unusual case of compensated cirrhosis with CSPH caused by hepatitis B, and we successfully adjust NSBBs drug treatment strategies monitoring by HVPG results and achieve response standards. Timely adjustment of NSBBs drug treatment strategies based on HVPG test results for patients with CSPH can improve the final response rate.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
